Mednet Logo
HomeHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

At what lab values (ferritin, TSAT%) would you offer IV iron therapy to patients with restless leg syndrome?

3
2 Answers

Mednet Member
Mednet Member
Hematology · Georgetown University School of Medicine

1. I am hopeful that practitioners will start understanding that ferritin alone is not enough to assess iron because of its acute phase reactivity. I like to order iron parameters after a 5-9 hour fast so the serum iron is not speciously elevated and get a ferritin and TSAT. If the ferritin is <30 a...

Are there still clinical situations in which you deliberately treat patients with a DOAC besides apixaban?

2
6 Answers

Mednet Member
Mednet Member
General Internal Medicine · University of Chicago

Thank you for your question. Apixaban has been my preferred agent for a long time for patients requiring therapeutic anticoagulation. Apixaban’s lower bleeding risk was shown prior to and now has additional evidence to support this with the COBRRA trial. The risk is also ameliorated by the safety in...

What GDMT do you recommend for patients with AL amyloidosis and systolic heart failure?

1 Answers

Mednet Member
Mednet Member
Cardiology · Memorial Sloan Kettering Cancer Center

You are correct that cardiac amyloidosis pts do not tolerate most of the GDMT. SGLT2i may be helpful for both diuresis as well as HFpEF, and we do try to start this. Generally they do not tolerate ARB/ACEI or even beta blockers. We find that torsemide seems to have better GI absorption and thus effi...

Do you routinely check serum phosphorus levels after IV iron therapy?

1
2 Answers

Mednet Member
Mednet Member
Hematology · Georgetown University School of Medicine

Only before and after FCM. I hold subsequent doses if phosphorus low. There is no need to monitor with the other formulations. For people needing multiple doses of IV iron (IBD, bariatric surgery, heavy uterine bleeding, angiodysplasia), I avoid FCM.

Do you recommend vitamin C supplementation with PO iron in patients with iron deficiency?

2 Answers

Mednet Member
Mednet Member
Hematology · Georgetown University School of Medicine

Vitamin C supplementation is unnecessary. Taking the iron with a glass of orange juice away from food and especially coffee optimizes absorption. That being said vitamin C does no harm. See vonSiebenthal et al eClinical Works 2023 (Lancet publication), Benson et al, Lancet Haem 2025 or Auerbach et a...

Would you supplement iron for low iron studies in absence of anemia?

2 Answers

Mednet Member
Mednet Member
Hematology · Georgetown University School of Medicine

The answer is absolutely and positively. Iron deficiency causes symptoms independent of anemia which include fatigue, brain fog, restless legs syndrome, and pagophagia and other forms of pica. You simply cannot dignify waiting for overt iron deficiency to develop in someone with symptomatic iron def...

Are there any alternative, hypofractionated RT courses for patients with DLBCL that can be used during the COVID-19 pandemic?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · David Geffen School of Medicine at UCLA

ILROG recently came out with guidelines pasted below: Synopsis of ILROG Recommendations for Administering Radiotherapy for Hematological Malignancies During Emergency Conditions of the COVID-19 Pandemic • We are facing an increased demand for RT to substitute or complement systemic therapy deemed i...

Do you offer enasidenib with azacitadine in AML with an IDH2 mutation for patients ineligible for intensive induction chemotherapy?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of California Davis Comprehensive Cancer Center

I typically do not give enasidenib with azacitidine upfront for patients with AML with IDH2 mutation and ineligible for intensive induction chemotherapy. Based on the results of the VIALE-A study (DiNardo et al, NEJM 2020), I usually give venetoclax with azacitidine to those patients. In addition to...

When would you use AVD + brentuximab instead of ABVD for newly diagnosed stage 3 or 4 Hodgkin lymphoma?

3
2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of British Columbia Faculty of Medicine

By reducing the risk of primary treatment failure from 23% to 18%, the ECHELON-1 study demonstrated that compared to ABVD, AVD + brentuximab vedotin reduces the risk of primary treatment failure by about 25% for patients with advanced-stage classic Hodgkin lymphoma. If given with prophylactic G-CSF,...

Do you routinely evaluate patients with collagen disorders or Ehlers-Danlos for platelet defects?

1
1 Answers

Mednet Member
Mednet Member
Hematology · University of Rochester

Yes, I routinely carry out a full hemostasis evaluation, including platelet aggregation and release studies, in patients referred to me with easy bruising and hypermobility with an increased Beighton score suggesting EDS and in those already diagnosed genetically with EDS. EDS patients typically hav...